All patients were assessed by flow-cytometry using PE-conjugated anti-CD38, APC-conjugated anti-CD19, FITC-conjugated CD5, and PE-, APC-, and FITC-conjugated isotype controls (BD-Pharmingen ...

Treatment with CM313, a novel anti-CD38 monoclonal antibody, can result in targeted clearance of CD38-positive cells, including plasma cells. We conducted a phase 1–2, open-label study to ...

Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or ...

The Transcreener ADPR Assay may identify the activity of human Cluster of Differentiation 38 (CD38) or Poly (ADP-ribose) glycohydrolase (PARG). CD38 regulates cellular NAD homeostasis by degrading ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38.

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...